Please login to the form below
trastuzumab
This page shows the latest trastuzumab news and features for those working in and with pharma, biotech and healthcare.
UK approval for Seagen’s oral HER2 inhibitor Tukysa
In 2019, Seagen announced that it had initiated another trial of Tukysa – the HER2CLIMB-02 study – that will compare Tukysa to placebo in combination with Kadcyla (ado-trastuzumab emtansine) in
Latest news
-
Roche’s diagnostic business sales offer a bright spot in Q4
treatments Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).
-
Roche gets EU approval for fixed-dose Herceptin/Perjeta combination
The new combination treatment, containing Herceptin (trastuzumab) and Perjeta (pertuzumab) with hyaluronidase, has been authorised for use for the treatment of early and metastatic HER2-positive breast cancer.
-
Pfizer CEO says COVID-19 vaccine efficacy data could come ‘soon’
Global revenues for its biosimilar also reach $424m, up 80% operationally, driven mostly by recent oncology launches of Ruxience (rituximab), Zirabev (bevacizumab) and Trazimera (trastuzumab) in the US and other global
-
AZ strengthens Daiichi Sankyo partnership with new ADC deal
acalabrutinib) and its recently approved, Daiichi-partnered HER2-targeting ADC, Enhertu (trastuzumab deruxtecan).
-
Roche cites COVID-19 and biosimilars in Q2 decline
Much of that decline can be attributed to increasing biosimilar competition to three of Roche’s key cancer therapies – Herceptin (trastuzumab), Avastin (bevacizumab) and Rituxan (rituximab).
More from news
Approximately 14 fully matching, plus 170 partially matching documents found.
Latest Intelligence
-
Surviving cancer: a new era for patients
The rise of the monoclonal antibody. Trastuzumab was the first monoclonal antibody tested in clinical trials, designed to inhibit human epidermal growth factor receptor 2 (HER2) which, when activated, promotes breast ... Trastuzumab successfully reduced
-
Cortellis Drugs to Watch in 2020 report
10. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) is also an ADC that targets HER2.
-
20 for 2020 – Five pharma companies to watch
The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... 4. Daiichi Sankyo. The fourth company on our list – Daiichi Sankyo – has something in common with the first.Our
-
2016: The year when deal-makers took stock?
Canada for biosimilar versions of Rituxan (rituximab) and Herceptin (trastuzumab). .
-
Deal Watch October 2016
Teva has paid $160m upfront with $60m refundable or creditable (presumably if registration fails) for rituximab (Rituxan) and trastuzumab (Herceptin), both in late phase III development. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
AVEO's financial head joins ImmunoGen
cancer treatment Kadcyla (trastuzumab emtansin) it developed in partnership with Roche.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Are biobetters a market access opportunity?
trastuzumab emtansine), received its first EU approval. for HER2+ metastatic breast cancer patients who did not respond to Herceptin and/or taxane.
-
The 2019 WHO essential medicine list: Narrowing the access gap to innovative cancer treatments
Roche’s Kadcyla (trastuzumab emtansine). the Committee stated that while it demonstrates relevant survival benefit, its use as second-line treatment of metastatic disease was considered not to be a priority
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Senior Content Editor - Biotechnology
-
Salary TBC
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
-
Account Management
-
Competitive Salary Offered
-
Principal Medical Writer
-
Varies on experience
- Pfizer helps fund biotech venture from former researchers at closed Kent facility
- Oxford University to investigate nasal spray delivery of AZ-partnered COVID-19 vaccine
- First dose of Pfizer/BioNTech vaccine reduces COVID-19 infection risk by 70%
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- New restrictions for AZ/Oxford COVID-19 vaccine despite EMA endorsement
- Moderna launches COVID-19 vaccine booster study to address new variants
- WHITE PAPER: Why do men die younger?
- Opdivo improves survival in oesophageal cancer
- Opdivo plus chemotherapy increases response in pre-surgery NSCLC patients
- UPDATE: AZ/Oxford University COVID-19 vaccine gets EU approval
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- Roche, Regeneron’s COVID-19 antibody cocktail cuts infection risk
PMHub
Purple Agency
An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....
Latest intelligence
- WHITE PAPER: Why do men die younger?
- It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...
- 3 tips to show patient diversity in your clinical trial materials
- Here are some useful tips to help get your hands on authentically diverse stock photos....
- Virtual congresses: video thrilled the cardio tsar
- Chris Ross explores the key learnings from a year of virtual congresses...
Quick links
Infographics
